Beximco Pharma. - Results for the year ended 30 June 2026
RNS Number : 2820CBeximco Pharmaceuticals PLC09 November 20269 November 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Results for the year ended 30 June 2026
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the year ended 30 June 2026.
Financial Highlights (consolidated)
- Net revenue increased 14.5% to Bangladesh Taka ("BDT") 56,265.9m / £347.5m (2024-25: BDT 49,120.4m / £295.6m
- Domestic sales increased 15.1% to BDT 51,852.5m / £320.3m (2024-25: BDT 45,046.9m / £271.1m)
- Export sales increased 8.3% to BDT 4,413.4m / £27.3m (2024-25: BDT 4,073.5m / £24.5m)
- Profit after tax increased 30.9% to BDT 9,160.8m / £56.6m (2024-25: BDT 6,998.9m / £42.1m)
- EPS for the year amounted to BDT 20.17 (2024-25: BDT 15.56)
- Recommended 60% cash dividend (BDT 6.00 per share)
Operational Highlights
Launched 8 generics in 19 presentations in Bangladesh
2 for the first time in Bangladesh
Completed 43 new registrations of 36 products across 18 countries worldwide
Launched anti-migraine drug Eletriptan tablets (20 mg and 40 mg) in the US Market
Launched Sotalol tablets (80 mg and 160 mg) in the Canadian Market
Commenced export to Lebanon
Handed over Triko, the first and only generic copy of breakthrough Cystic Fibrosis drug Trikafta, to patients from 6 countries
Post Period Highlights
Launched 5 generics in 6 presentations in Bangladesh
2 for the first time in Bangladesh
Completed 9 registrations of 8 products across 6 countries
Nominated for the “The Scrip Awards 2026” in the category of Community Partnership of the Year
Beximco Pharma Managing Director Iqbal Ahmed commented:
“We are pleased to announce continued double-digit revenue growth for the financial year. In a challenging macro-economic environment, the delivery of such strong growth is testament to the underlying strength of the business. As always, we have maintained our focus on operational delivery, strengthened our product portfolio and continued to expand our presence in domestic and international markets.
“We are especially proud of the Triko launch, the world’s first and only generic copy of breakthrough Cystic Fibrosis drug Trikafta, providing patients with transformative access to a lifesaving medicine at a fraction of the originator price. This launch strongly reflects our commitment to ensuring that patients around the world have access to affordable and high-quality medicines.
“Whilst we continue to experience ongoing global macro-economic challenges, we remain focused on executing on our strategy and navigating the evolving business environment.”
Exchange rates of £1=Taka 161.9021 for 2025-26 and £1=Taka 166.1585 for 2024-25 have been used in this announcement.
The full year accounts can be viewed at the Company's website: www.beximcopharma.com.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of financial position
As at 30 June 2026
30 June 2026
Amount in Taka
30 June 2025
ASSETS
Property, plant and equipment
45,602,684,285
43,541,872,125
Right-of-use assets
359,772,325
485,613,049
Intangible assets
4,551,852,390
4,694,133,629
Deferred tax asset
19,651,021
44,078,388
Goodwill
674,570,185
674,570,185
Investment in associates
15,364,734
-
Other investments
6,733,457
20,974,134
Total non-current assets
51,230,628,397
49,461,241,510
Inventories
13,988,598,555
13,586,475,819
Spares and supplies
1,010,233,353
799,643,860
Trade and other receivables
3,669,562,137
3,628,788,364
Loans, advances, deposits and prepayments
3,220,129,543
2,814,492,520
Advance income tax
402,401,544
356,507,571
Short term investment
950,000,000
900,000,000
Cash and cash equivalents
6,668,012,479
1,700,096,960
Total current assets
29,908,937,611
23,786,005,094
TOTAL ASSETS
81,139,566,008
73,247,246,604
EQUITY AND LIABILITIES
Share capital
4,461,120,890
4,461,120,890
Share premium
5,269,474,690
5,269,474,690
Excess of issue price over face value of GDRs
1,689,636,958
1,689,636,958
Capital reserve on merger
294,950,950
294,950,950
Revaluation surplus
1,130,820,610
1,133,870,432
Unrealized gain/(loss)
3,908,281
18,148,958
Retained earnings
49,241,292,553
40,239,934,223
Total shareholders' equity
62,091,204,932
53,107,137,101
Non-controlling interest
4,103,149,348
3,977,498,766
TOTAL EQUITY
66,194,354,280
57,084,635,867
Long term borrowings-net of current maturity
1,738,988,035
1,503,595,560
Liability for gratuity and WPPF
3,395,313,958
3,688,238,284
Deferred tax liability
2,758,009,938
2,575,780,261
Non-current liabilities
7,892,311,931
7,767,614,105
Short term borrowings
2,303,467,001
2,025,393,637
Long term borrowings-current maturity
586,628,854
1,436,751,660
Trade and other payables
1,952,971,347
2,927,851,030
Accrued expenses
1,422,556,087
1,174,096,256
Dividend payable
137,953,976
302,271,608
Income tax payable
649,322,532
528,632,441
Total current liabilities
7,052,899,797
8,394,996,632
Total liabilities
14,945,211,728
16,162,610,737
TOTAL EQUITY AND LIABILITIES
81,139,566,008
73,247,246,604
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2026
Amount in Taka
30 June 2026
30 June 2025
Net revenue
56,265,856,224
49,120,354,035
Cost of goods sold
(28,870,192,837)
(26,825,860,744)
Gross profit
27,395,663,387
22,294,493,291
General and administrative expenses
(1,554,380,986)
(1,401,982,177)
Selling, marketing and distribution expenses
(13,395,060,921)
(11,044,794,908)
Operating expenses
(14,949,441,907)
(12,446,777,085)
Profit from operations
12,446,221,480
9,847,716,206
Other income
790,337,629
608,998,701
Finance cost
(656,352,588)
(991,706,942)
Share of profit of associates
15,364,734
-
Profit before tax and WPPF
12,595,571,255
9,465,007,965
Contribution to WPPF
(609,711,618)
(460,957,986)
Profit before tax
11,985,859,637
9,004,049,979
Current tax
(2,617,477,105)
(1,986,172,572)
Deferred tax
(207,542,476)
(19,007,698)
Income tax expenses
(2,825,019,581)
(2,005,180,270)
Profit after tax
9,160,840,056
6,998,869,709
Owners of the Company
8,997,423,076
6,940,622,589
Non-controlling interest
163,416,980
58,247,120
Profit/(loss) attributable
9,160,840,056
6,998,869,709
Other comprehensive income/(loss)
(14,240,677)
762
Total comprehensive income
9,146,599,379
6,998,870,471
Owners of the Company
8,983,182,399
6,940,623,351
Non-controlling interest
163,416,980
58,247,120
Total comprehensive income attributable
9,146,599,379
6,998,870,471
Earnings per share (EPS)
20.17
15.56
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of changes in equity
For the year ended 30 June 2026
For the year ended 30 June 2026
Amount in Taka
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the Company
Non-controlling interests
Total
Balance as on 01 July 2025
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,133,870,432
18,148,958
40,239,934,223
53,107,137,101
3,977,498,766
57,084,635,867
Total comprehensive income:
Profit for the year
-
-
-
-
-
-
8,997,423,076
8,997,423,076
163,416,980
9,160,840,056
Other comprehensive income/(loss)
-
-
-
-
-
(14,240,677)
-
(14,240,677)
-
(14,240,677)
Transactions with the shareholders:
Cash dividend
-
-
-
-
-
-
-
-
(37,766,398)
(37,766,398)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(3,935,254)
-
3,935,254
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
885,432
-
-
885,432
-
885,432
Balance as on 30 June 2026
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,130,820,610
3,908,281
49,241,292,553
62,091,204,932
4,103,149,348
66,194,354,280
Net asset value (NAV) per share 139.18
For the year ended 30 June 2025
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the Company
Non-controlling interests
Total
Balance as on 01 July 2024
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,137,305,789
18,148,196
35,079,327,271
47,949,964,744
3,952,938,136
51,902,902,880
Total comprehensive income:
Profit for the year
-
-
-
-
-
-
6,940,622,589
6,940,622,589
58,247,120
6,998,869,709
Other comprehensive income/(loss)
-
-
-
-
-
762
-
762
-
762
Transactions with the shareholders:
Cash dividend
-
(1,784,448,356)
(1,784,448,356)
(33,686,490)
(1,818,134,846)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(4,432,719)
-
4,432,719
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
997,362
-
-
997,362
-
997,362
Balance as on 30 June 2025
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,133,870,432
18,148,958
40,239,934,223
53,107,137,101
3,977,498,766
57,084,635,867
Net asset value (NAV) per share 119.04
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of cash flows
For the year ended 30 June 2026
30 June 2026
Amount in Taka
30 June 2025
Cash flows from operating activities:
Cash receipts from customers and others
56,660,083,852
49,891,648,809
Cash paid to suppliers and employees
(44,249,161,693)
(39,742,461,113)
Cash generated from operations
12,410,922,159
10,149,187,696
Interest paid
(652,368,635)
(976,729,205)
Interest received
298,941,277
19,922,699
Income tax paid
(2,542,680,987)
(1,969,795,120)
Net cash generated from operating activities
9,514,813,814
7,222,586,070
Cash flows from investing activities:
Acquisition of property, plant and equipment
(3,812,442,309)
(2,781,313,389)
Intangible assets
(233,252,022)
(247,936,908)
Disposal of property, plant and equipment
11,223,226
60,327,928
Disposal of intangible assets
18,255,000
-
Dividend received
1,088,746
974,510
Short term investment
(50,000,000)
(700,000,000)
Net cash used in investing activities
(4,065,127,359)
(3,667,947,859)
Cash flows from financing activities:
Net increase/(decrease) in long term borrowings
(559,616,178)
(152,518,998)
Net increase/(decrease) in short term borrowings
278,073,364
(971,266,326)
Dividend paid
(202,084,029)
(1,603,086,311)
Net cash from/(used in) financing activities
(483,626,843)
(2,726,871,635)
Increase/(decrease) in cash and cash equivalents
4,966,059,612
827,766,576
Opening cash and cash equivalents
1,700,096,960
854,105,649
Effect of exchange rate changes on cash and cash equivalents
1,855,907
18,224,735
Closing cash and cash equivalents
6,668,012,479
1,700,096,960
Net operating cash flows per share
21.33
16.19
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDFR FLFETLSLTIIR